ReviewGenes & cancer2014
ALK-rearrangements and testing methods in non-small cell lung cancer: a review.
Review in Genes & cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 73 citations in OpenAlex.
- Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab.International journal of molecular sciences · 2026Article
- Elastase reduces background autofluorescence in ALK fluorescence in situ hybridization assays for lung cancers.Biomedical journal · 2025Article
- [Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.Journal of clinical medicine · 2024Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Recent Advances in Rapid and Highly Sensitive Detection of Proteins and Specific DNA Sequences Using a Magnetic Modulation Biosensing System.Sensors (Basel, Switzerland) · 2022Review
- Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.The clinical respiratory journal · 2022Article
- An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.Bosnian journal of basic medical sciences · 2022Review
- A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.Cancer research and treatment · 2021Article
- Development of a novel ALK rearrangement screening test for non-small cell lung cancers.PloS one · 2021Article
- Analysis of lung biopsies using the 2015 WHO criteria and detection of sensitizing mutations--a single-institution experience of 5032 cases.Diagnostic pathology · 2020Article
- Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.Molecules (Basel, Switzerland) · 2020Review
- Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2019Review
- Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.Clinical pharmacokinetics · 2019Review
- Hypermethylation ofOncology letters · 2018Article
- Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.Medical oncology (Northwood, London, England) · 2018Review
- Role and targeting of anaplastic lymphoma kinase in cancer.Molecular cancer · 2018Review
- S100A4 promotes lung tumor development through β-catenin pathway-mediated autophagy inhibition.Cell death & disease · 2018Article
- Review
- AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling.FEBS open bio · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver mutation in anaplastic non-Hodgkin's lymphoma. Dysregulated ALK expression is now an identified driver mutation in nearly twenty different human malignancies, including 4-9% of non-small cell lung cancers (NSCLC). The tyrosine kinase inhibitor crizotinib is more effective than standard chemotherapeutic agents in treating ALK positive NSCLC, making molecular diagnostic testing for dysregulated ALK expression a necessary step in identifying optimal treatment modalities. Here we review ALKmediated signal transduction pathways and compare the molecular protocols used to identify dysregulated ALK expression in NSCLC. We also discuss the use of crizotinib and second generation ALK tyrosine kinase inhibitors in the treatment of ALK positive NSCLC, and the known mechanisms of crizotinib resistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.